Citadel Advisors
TARA icon

Citadel Advisors’s Protara Therapeutics TARA Stock Holding History

Citadel Advisors’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$781K Buy
149,900
+120,400
+408% +$713K ﹤0.01% 8246
2025
Q4 		$157K Buy
29,500
+16,500
+127% +$91.7K ﹤0.01% 11263
2025
Q3 		$56.5K Sell
13,000
-8,200
-39% -$26.6K ﹤0.01% 12134
2025
Q2 		$64.2K Sell
21,200
-23,200
-52% -$80K ﹤0.01% 11639
2025
Q1 		$189K Buy
44,400
+44,200
+22,100% +$197K ﹤0.01% 10531
2024
Q4 		$1.06K Sell
200
-8,800
-98% -$28.4K ﹤0.01% 14230
2024
Q3 		$16.5K Buy
9,000
+600
+7% +$1.23K ﹤0.01% 12931
2024
Q2 		$17.5K Buy
8,400
+4,600
+121% +$13.4K ﹤0.01% 12751
2024
Q1 		$15.2K Buy
3,800
+3,500
+1,167% +$11.3K ﹤0.01% 13198
2023
Q4 		$561 Buy
+300
New +$442 ﹤0.01% 14005
2023
Q1 		– Sell
-800
Closed -$2.14K – 15503
2022
Q4 		$2.14K Buy
+800
New +$2.52K ﹤0.01% 14373
2021
Q3 		– Sell
-11,300
Closed -$110K – 14627
2021
Q2 		$110K Buy
+11,300
New +$128K ﹤0.01% 12837

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Citadel Advisors's TARA Position: Q1 2026 in Review

Citadel Advisors increased its Protara Therapeutics (TARA) stake by 19% in Q1 2026, buying an estimated $989K and bringing the position to 1,068,558 shares worth $5.57M. The position accounts for ﹤0.01% of the portfolio, ranked #4168.

Citadel Advisors first reported a position in TARA in Q1 2017 and has held it in 25 quarters since. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • Citadel Advisors held 1,068,558 shares of Protara Therapeutics worth $5.57M as of Q1 2026.
  • Citadel Advisors bought 167,017 Protara Therapeutics shares in Q1 2026, an estimated $989K.
  • Protara Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4168 holding.
  • Citadel Advisors first reported a position in Protara Therapeutics in Q1 2017 and has held it in 25 quarters since.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.